Regarding the molecular mechanism underlying the progression of sarcopenia in the SDT group, disruption to insulin/IGF-1-Akt signaling due to insulin resistance and low serum IGF-1 levels was considered to provoke abnormalities in muscle strength and mass in the SDT group (Figure 11). The gene discussed is AKT1; the disease is sarcopenia.